Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Identification of chemokines and cytokines offers new hope for inflammatory myopathy patients

10.09.2002


The inflammatory myopathies comprise three different entities: polymyositis, inclusion body myositis and dermatomyositis. People in all age groups can be affected by major muscle weakness and pain, and show evidence of muscle fiber breakdown in the serum. Autoimmune pathogenetic mechanisms have been identified in each inflammatory myopathy, but the antigen(s) recognized by the autoreactive inflammatory cells and the factors eliciting the aberrant immune responses remain unknown. Currently, patients are treated with corticosteroids with variable success rates and at a high cost of side-effects.



The ongoing research is aimed at identifying the factors that guide the trafficking of inflammatory cells from the blood to the inflamed muscle tissue. A new study reports the differential expression of chemokines and their receptors in each inflammatory myopathy. Chemokines represent a family of small-molecular weight cytokines that have an important role in the migration of distinct leukocyte subsets to the sites of inflammation. The chemokines monocyte chemoattractant protein-1 (MCP-1) and stromal derived factor (SDF-1a and SDF-1b) and their receptors are strongly expressed whereas a number of others are undetectable.

Blocking the autoimmune cascade by targeting chemokines or chemokine receptors has given excellent results in animal models of other immune diseases. The present work identifies the candidates for selective immune intervention in patients suffering autoimmune inflammatory myopathies and may well lead to more selective treatment modalities with less side-effects than the currently available drugs.


Previous research by this group had focused on other factors that control recruitment and activation of immune cells, such as cell adhesion molecules and cytokines. Based in part on data that described the role of the cytokine tumor necrosis factor-a (TNF-a) and its receptors in inflammatory myopathy muscle biopsies, preliminary clinical studies with TNF-blocking monoclonal antibodies are now being initiated in several hospitals. "It is very encouraging to see data obtained from clinically oriented research move from the laboratory bench to the clinical treatment phase in just a few years time", said Professor Jan De Bleecker who is the first author of these papers.

Jan DE BLEECKER | alfa

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>